Skip to Content

'
Dean Anthony Lee, MD, PHD

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Faculty, Graduate School of Biomedical Sciences, The University of Texas Health Sciences Center, Houston, TX

Bio Statement

Contact Information

Phone- 713-563-5404

Email- dalee@mdanderson.org


Clinical Focus

My clinical practice is in caring for children undergoing hematopoietic stem cell transplantation (HSCT) for malignant or non-malignant diseases.  My clinical research is focused on developing trials of adoptive immune therapy with NK cells, particularly for myeloid malignancies within the context of transplant.  I also participate in clinical trials of autologous HSCT for neurologic injuries.  Investigator-initiated clinical trials that are open or in development include

- a phase I clinical trial for reinduction of AML using haploidentical NK cells and a fusion protein called ALT-801- produced by Altor BioSciences- that targets NK cells to cells that express p53

- a phase I clinical trial testing the safety and feasibility of IL-21-expanded NK cells (developed in my laboratory) in combination with FLAG chemotherapy for reinduciton of AML

- a phase I clinical trial testing the safety and feasibility of IL-21-expanded NK cells in combination with transplant for AML

- a phase I clinical trial testing the safety and feasibility of IL-21-expanded NK cells in combination with rituximab and lenalidomide for lymphoma

- a phase I clinical trial testing the safety and feasibility of IL-21-expanded NK cells in combination with anti-GD2 mAb for neuroblastoma

 

Laboratory Focus

Congruent with my clinical practice and clinical research, my laboratory research is focused on improving NK-cell immunotherapy against cancer and understanding NK cell biology, based on a system of ex vivo NK cell expansion, based on genetically-engineered artificial APCs expressing a membrane-bound IL-21 fusion.  This system enables our research in the following key areas:

* Adoptive immunotherapy of pediatric cancers

* Ex vivo epanded and gene-modified NK cells

* STAT3 signaling in NK cells

* post-maturation KIR licensing and repertoire molding

* Chimeric antigen receptors designed with NK-cell like endodomain signaling

* Platforms and devices for non-integrating (mRNA) gene transfer

* Transposon-based gene modification of NK cells

* Immunomodulatory drugs to enhance NK cell function

* Trogocytosis for non-genetic modification of NK cells


UT Graduate School website: http://gsbs.uth.tmc.edu/tutorial/lee_d.html

PubMed publication list: http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1F_CsFkIaUGdcSy2889Vmwo/

 

Collaborative Research Program

We work closely with the laboratory of Laurence Cooper and collaborate with many other investigators in academia and industry. The goals of these collaborations are always to advance the field of cellular immunotherapy and translate those advancements to improved long-term, disease-free survival of patients with pediatric malignancies and hematologic diseases.

 

Lab Meeting

Friday 9 A.M. in SCRB1 Conference Room

 

Current Lab Members

* Cecele Denman (Senior Research Associate)

* Marie Fouad (Undergrad student)

* Anitha Gururajan, MS

* Prasad Phatarpekar (PhD Student, GSBS)

* Anish Ray, MD (Clinical Postdoctoral Fellow)

* Howard Rossoff (PhD Student, GSBS)

* Vladimir Senyukov, PhD (Research Investigator)

* Srinivas Somanchi, PhD (Research Investigator)


Lab Alumni (When in my lab -> Current location):

William Choi (Undergrad, Houston Baptist University -> MD/PhD Student, Baylor College of Medicine)

Nichole Corless (Undergrad, Fresno Pacific University -> Graduate School, CSU Fresno)

Santiago De La Garza (High School Student -> Medical Student, Baylor College of Medicine)

MariRene Font (High School Student -> Undergrad, Notre Dame)

Jeff Friesen (Undergrad, Fresno Pacific University -> School of Medicine, UC Irvine)

David Fujihara (Undergrad, Fresno Pacific University -> Undergrad, Fresno Pacific University)

Jonathan Hanna (High School Student -> Undergrad, Duke University)

Jennifer Johnson (Undergrad, Fresno Pacific University -> School of Medicine, St. Louis Univ)

Tim Kahn (Undergrad, Fresno Pacific University -> Undergrad, Fresno Pacific University)

Lisa Kopp (Clinical Postdoctoral Fellow -> Assistant Professor, UNM Tucson)

Stephen Lee (High School Student -> Undergrad, Sam Houston State Univ)

Brian Liu (High School Student -> Premed, Johns Hopkins)

Bhavisha Patel (School of Medicine, Univ Illinois -> Medicine Resident, U Wisconsin)

Ivan Petrich (Undergrad, Fresno Pacific University -> Grad School, Univ Utah)

Romina Sabella-River (Clinical Postdoctoral Fellow -> Staff Physician, Texas Children's Pediatric Associates)

Aaron Seo (Undergrad, U Texas -> MD/PhD Student, University of Washington)

David Walker (Undergrad, Carlton College)

Jennifer Williams (Undergrad, Fresno Pacific University -> School of Medicine, Washington Univ)

Shuguo Zhu (Postdoctoral Fellow -> Assistant Professor, Shanghai Jiao Tong University)

Education & Training

Degree-Granting Education

1996 Loma Linda University, Loma Linda, CA, MD, Medicine
1995 Loma Linda University, Loma Linda, CA, PHD, Microbiology and Molecular Genetics
1987 Fresno Pacific College, Fresno, CA, BA, Natural Sciences

Postgraduate Training

7/2000-6/2003 Fellowship, Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX, David G. Poplack
7/1996-6/1999 Residency, Pediatrics, Loma Linda University, Loma Linda, CA, Richard E. Chinnock

Board Certifications

11/2004 American Board of Pediatrics: Pediatric Hematology/Oncology
10/1999 American Board of Pediatrics: General Pediatrics

Experience/Service

Other Appointments/Responsibilities

Steering Committee Member for the Department of Immunology, UT MD Anderson Cancer Center, Houston, TX, 4/2012-present
Chief Fellow, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, 7/2002-6/2003
Chief Resident, Loma Linda University Children's Hospital, Loma Linda, CA, 7/1999-6/2000

Institutional Committee Activities

Member, Postdoctoral Advisory Committee (PDAC), UT MD Anderson Cancer Center, 9/2011-present
Member, Institutional Bio-Safety Committee, UT MD Anderson Cancer Center, 9/2011-8/2013
Member, Pediatric Clinical Research SOP Development, The Children's Cancer Hospital of UT MD Anderson Cancer Center, 2011
Chair, Policy CLN0508 Revision Committee, UT MD Anderson Cancer Center, 2008-2009
Member, Clinical Practice Guidelines Committee, Texas Children's Cancer Center, 2004-2006
Member, Chemotherapy Safety Committee, Texas Children's Cancer Center, 2003-2006
Member, Protocol Review Committee/Data Safety Monitoring Board, Baylor College of Medicine, 2003-2006
Member, Education Committee, Pediatrics Hematology/Oncology Section, Baylor College of Medicine, 2002-2004
Member, Resident Advisory Committee, Loma Linda University Medical Center, 1998-2000

Honors and Awards

2009 Excellent Reviewer Award, Office of Scientific Review, UT MD Anderson Cancer Center
2008-2013 Physician Scientist Program, UT MD Anderson Cancer Center
2005-2010 Young Investigator, Stem Cell Transplant Committee, Children's Oncology Group
2003-2005 ASCO Young Investigator Award, American Society of Clinical Oncology
2003-2004 ASH Clinical Research Training Institute, American Society of Hematology
1999 Hertha Ehlers Resident Award of Excellence, Loma Linda University
1998 Junior Resident of the Year Award, Loma Linda University
1995 National Student Research Forum, Galveston, Texas
1992-1993 Selma Andrews Fellowship, Loma Linda University
1992 Student Research Grant, Walter E. MacPherson Society
1987-1989 Graduate Fellowship, California State
1987 Alpha Chi Honor Society, Fresno Pacific College
1983-1987 President's Scholarship, Fresno Pacific College

Professional Memberships

American Society for Clinical Oncology
Member, 2002-present
American Society of Gene Cell Therapy
Member, 2009-present
American Society of Hematology
Member, 2003-present
American Society of Pediatric Hematology/Oncology
Member, 2004-present
Children's Oncology Group, Bethesda, MD
Full Member, 2003-present
International Society for Cell Therapy
Member, 2007-present
JMML Foundation International Working Group
Member, 2008-present
South Plains Oncology Group, Pediatric Scientific Research Council
Member, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Cairo M, Tarek N, Lee DA, Delaney C. Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients. In Press.
2. Sandberg DI, Rytting M, Zaky W, Kerr M, Ketonen L, Kundu U, Moore BD, Yang G, Hou P, Sitton C, Cooper LJ, Gopalakrishnan V, Lee DA, Thall PF, Khatua S. Methotrexate Administration Directly into the Fourth Ventricle in Children with Malignant Fourth Ventricular Brain Tumors: A Pilot Clinical Trial. Journal of Neuro-Oncology. In Press.
3. Kongtim P, Lee DA, Cooper LJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy. Biol Blood Marrow Transplant. e-Pub 7/11/2015. PMID: 26172479.
4. Fei Fei, Lim Min, George Aswathi, Kirzner Jonathan, Lee D, Seeger Robert, Groffen John, Abdel-Azim Hisham, Heisterkamp Nora. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. Leukemia 20(4):788-97, 4/2015. e-Pub 8/2014. PMCID: PMC4334757.
5. Liao GP, Harting MT, Hetz RA, Walker PA, Shah SK, Corkins CJ, Hughes TG, Jimenez F, Kosmach SC, Day MC, Tsao K, Lee DA, Worth LL, Baumgartner JE, Cox CS. Autologous Bone Marrow Mononuclear Cells Reduce Therapeutic Intensity for Severe Traumatic Brain Injury in Children. Pediatr Crit Care Med. e-Pub 1/2015. PMCID: PMC4351120.
6. Lee DA. The off-target effects of nonspecific NK cells. Blood 125(5):744-5, 1/2015. PMID: 25634612.
7. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-Atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 12/2014. e-Pub 9/2014. PMCID: PMC4343203.
8. Deniger DC, Maiti S, Mi T, Switzer K, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls H,Lee DA, Bast RC, Champlin RE, Cooper LJ. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res, 11/2014. PMCID: PMC4233015.
9. Romain G, Senyukov V, Rey-Villamizar N, Merouane A, Kelton W, Liadi I, Mahendra A, Charab W, Georgiou G, Roysam B, Lee DA, Varadarajan N. Antibody Fc-engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood 124(22), 11/2014. PMCID: PMC4239333.
10. Guma SR,Lee DA, Ling Y, Gordon N, Kleinerman ES. Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer 61(8):1362-8, 8/2014. e-Pub 3/2014. PMCID: PMC4144337.
11. Parmar S, DeLima M, Worth L, Petropoulos D, Lee D, Cooper L, Kongtim P, Alousi A, Hosing C, Popat U, Kebriaei P, McNiece I, Shpall E, Rondon G, Champlin R. Is there an expiration date for a cord blood unit in storage? Nature 49(8):1109-12, 8/2014. PMCID: PMC4219634.
12. Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJ. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 111(29):10660-5, 7/2014. e-Pub 7/2014. PMCID: PMC4115509.
13. Zhu S, Phatarpekar PV, Denman CJ, Senyukov VV, Somanchi SS, Nguyen-Jackson HT, Mace EM, Freeman AF, Watowich SS, Orange JS, Holland SM, Lee DA. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood 124(3):403-11, 7/2014. e-Pub 6/2014. PMCID: PMC4102712.
14. Rushworth D, Jena B, Olivares S, Maiti S, Briggs N, Somanchi S, Dai J, Lee DA, Cooper LJ. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37(4):204-13, 5/2014. PMCID: PMC4139067.
15. Guma SR, Lee DA, Yu L, Gordon N, Hughes D, Stewart J, Wang WL, Kleinerman ES. Natural Killer Cell Therapy and Aerosol Interleukin-2 for the Treatment of Osteosarcoma Lung Metastasis. Pediatr Blood Cancer 61(4):618-26, 4/2014. e-Pub 10/2013. PMCID: PMC4154381.
16. Bhatnagar P, Alauddin M, Bankson JA, Kirui D, Seifi P, Huls H, Lee DA, Babakhani A, Ferrari M, Li KC, Cooper LJ. Tumor Lysing Genetically Engineered T Cells Loaded with Multi-Modal Imaging Agents. Sci Rep 4:4502, 2014. e-Pub 3/2014. PMCID: PMC3968458.
17. Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau Ching C, Gottschalk SM, Hughes, DPM, Kleinerman ES,Lee DA. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharmacology Research. e-Pub 11/2013. PMCID: PMC4014531.
18. Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJN, Decker WK, Li S, Robinson SN, Kekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burke J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLOS ONE 18(8(10)):e76781, 10/2013. PMCID: PMC3800010.
19. Levy AS, Pyke-Grimm KA, Lee DA, Palla SL, Naranjo A, Saulnier Sholler G, Gratias E, Maloney K, Parshankar F, Lee-Scott M, Beierle EA, Gow K, Kim GE, Hunger S, Smith FO, Horton TM. Mentoring in Pediatric Oncology: A Report from the Children's Oncology Group Young Investigator Committee. J Pediatr Hematol Oncol 35(6):456-461, 8/2013. PMCID: PMC3839621.
20. Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJ. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122(8):1341-9, 8/2013. e-Pub 6/2013. PMCID: PMC3750336.
21. Kopp LM, Ray A, Denman CJ, Senyukov VS, Somanchi SS, Zhu S, Lee DA. Decitabine has a biphasic effect on natural Killer cell viability, phenotype, and function under proliferative conditions. Mol Immunol 54(3-4):296-301, 7/2013. e-Pub 1/2013. PMID: 23328088.
22. Sheard MA, Asgharzadeh S, Liu Y, Lin TY, Wu HW, Ji L, Groshen S, Lee DA, Seeger RC. Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother 36(5):319-29, 6/2013. NIHMSID: NIHMS492158.
23. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, Lee DA, Kaufman DS. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med 2(4):274-83, 4/2013. e-Pub 3/2013. PMCID: PMC3659832.
24. Shibina A, Seidel D, Somanchi SS, Lee DA, Stermann A, Maurer BJ, Lode HN, Reynolds CP, Huebener N. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med (Berl) 91(4):459-72, 4/2013. e-Pub 9/2012. PMID: 23052481.
25. Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ, Lee DA, Seeger RC. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res 19(8):2132-43, 4/2013. e-Pub 2/2013. PMCID: PMC3658308.
26. Wang X, Lee DA, Wang Y, Wang L, Yao Y, Lin Z, Cheng J, Zhu S. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clin Exp Immunol 172(1):104-12, 4/2013. PMCID: PMC3719936.
27. Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S,Lee DA, Champlin RE, Cooper LJ. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 21(3):638-47, 3/2013. e-Pub 1/2013. PMCID: PMC3589159.
28. Das CM, Taylor P, Gireud M, Singh A, Lee DA, Fuller G, Ji L, Fangusaro J, Rajaram V, Goldman S, Eberhart C, Gopalakrishnan V. The Deubiquitylase USP37 Links REST to the Control of p27 Stability and Cell Proliferation. Oncogene 32(13):1691-701, 3/2013. e-Pub 6/2012. PMCID: PMC3435483.
29. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36(2):112-23, 2/2013. PMCID: PMC3568214.
30. Bhatnagar P, Li Z, Choi Y, Guo J, Li F, Lee DY, Figliola M, Huls H, Lee DA, Zal T, Li KC, Cooper LJ. Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. Integr Biol (Camb) 5(1):231-8, 1/2013. e-Pub 10/2012. PMCID: PMC3713485.
31. Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJ. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One 8(3):e57838, 2013. e-Pub 3/2013. PMCID: PMC3585808.
32. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso N, Wu MF, Liu H, Kew Y, Grossman RG, Powell S, Lee DA, Ahmed N, Gottschalk S. T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. Mol Ther. e-Pub 10/2012. PMCID: PMC3589173.
33. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovitch B,Lee DA, Champlin RE, Bonini C, Naldini L, Rebar EJ, Gregory PD, Holmes MC, Cooper LJ. A Foundation for universal T-cell based immunotherapy: T-cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119(24):5697-705, 6/2012. e-Pub 4/2012. PMCID: PMC3382929.
34. Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node homing of ex vivo expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood 119(22):5164-72, 5/2012. e-Pub 4/2012. PMCID: PMC3418772.
35. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23(5):444-50, 5/2012. e-Pub 1/2012. PMCID: PMC3360496.
36. Farhan S,Lee DA, Champlin RE, Ciurea SO. NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy 4(3):305-13, 3/2012. e-Pub 2/2012. PMCID: PMC4037320.
37. O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJ. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep 2:249, 2012. e-Pub 2/2012. PMCID: PMC3278154.
38. Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee DA, Yvon E, Finney H, Lawson A, Brenner M, Biondi A, Biagi E, Rousseau R. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTLs against CD33+ acute myeloid leukemia (AML). Adv Hematol 2012:683065, 2012. e-Pub 1/2012. PMCID: PMC3261457.
39. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. PLoS One 7(1):e30264, 2012. e-Pub 1/2012. PMCID: PMC3261192.
40. Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mátés L, Izsvák Z, Ivics Z, Lee DA, Champlin RE, Cooper LJ. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 18(9):849-56, 9/2011. e-Pub 3/2011. PMCID: PMC4083583.
41. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Res 71(10):3516-27, 5/2011. e-Pub 5/2011. PMCID: PMC3096697.
42. Cox CS, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK, Ewing-Cobbs L, Hasan KM, Day MC, Lee DA, Jimenez F, Gee A. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery 68(3):588-600, 3/2011. PMID: 21192274.
43. Somanchi SS, Senyukov VV, Denman CJ, Lee DA. Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells. J Vis Exp(48), 2011. e-Pub 2/2011. PMCID: PMC3180743.
44. Choi Y, Yuen C, Maiti SN, Olivares S, Gibbons H, Huls H, Raphael R, Killian TC, Stark DJ, Lee DA, Torikai H, Monticello D, Kelly SS, Kebriaei P, Champlin RE, Biswal SL, Cooper LJ. A High Throughput Microelectroporation Device to Introduce a Chimeric Antigen Receptor to Redirect the Specificity of Human T cells. Biomed Microdevices 12(5):855-63, 10/2010. PMCID: PMC4109048.
45. Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE,Lee DA, Gopalakrishnan V. Chromatin remodeling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer 46(15):2771-80, 10/2010. PMCID: PMC3025305.
46. Davies JK, Singh H, Huls H, Yuk D,Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ. Combining CD 19-redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 70(10):3915-3924, 5/2010. e-Pub 4/2010. PMCID: PMC2873153.
47. Zhu S,Lee DA, Li S. IL12 and IL27 sequential gene therapy via intramuscular electroporation. J Immunol 184(5):2348-2354, 3/2010. e-Pub 2/2010. PMCID: PMC2824785.
48. Lee DA, Verneris MR, Campana D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol 651:61-77, 2010. PMID: 20686960.
49. Frugé E, Margolin J, Horton T, Venkateswaran L, Lee DA, Yee DL, Mahoney D. Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatr Blood Cancer 55(6):1180-4, 2010. PMID: 20589622.
50. Hurton LV, Siddik RI, Singh H, Olivares S, Rabinovich BA, Tian R, Mojsilovic D, Hildebrand W,Lee DA, Kelly SS, Champlin R, Shpall EJ, Fernandez-Vińa M, Cooper LJ. Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. Leukemia 24(5):1059-62, 2010. PMCID: PMC4135727.
51. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H,Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. piggyBac transposon/transposase system to generate CD19-specific T cells for treatment of B-lineage malignancies. Hum Gene Ther 21(4):427-37, 2010. PMCID: PMC2938363.
52. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cavé H, Clappier E, van Dongen JJ, Balgobind BV, van den Heuvel-Eibrink MM, Beverloo HB, Panzer-Grümayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan LC, Yip SF, Krzywinski M, Eckert C, Möricke A, Schrappe M, Alonso CN, Schäfer BW, Krauter J, Lee DA, Zur Stadt U, Te Kronnie G, Sutton R, Izraeli S, Trakhtenbrot L, Lo Nigro L, Tsaur G, Fechina L, Szczepanski T, Strehl S, Ilencikova D, Molkentin M, Burmeister T, Dingermann T, Klingebiel T, Marschalek R. New insights to the MLL recombinome of acute leukemias. Leukemia 23(8):1490-9, 2009. PMID: 19262598.
53. Singh H, Najjar AM, Olivares S, Nishii R, Mukhopadhyay U, Alauddin M, Manuri PR, Huls H,Lee DA, Dotti G, Bollard C, Simmons PJ, Shpall EJ, Champlin RE, Gelovani JG, Cooper LJ. PET imaging of T cells derived from umbilical cord blood. Leukemia 23(3):620-2, 2009. PMID: 18830258.
54. Lee DA, Tatevian N, Herring RA, McClain KL. EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH. Pediatr Blood Cancer 50(3):728-730, 3/2008. PMID: 17243127.
55. Choi WT, Folsom MR, Azim MF, Meyer C, Kowarz E, Marschalek R, Timchenko NA, Naeem RC,Lee DA. C/EBPbeta suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL. Cancer Genet Cytogenet 177(2):108-14, 2007. PMID: 17854664.
56. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR, [Lee DA]. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 46(4):414-421 (Cited as COG Transplant Discipline Committee member), 4/2006. PMID: 16463346.
57. Barshes NR, Myers GD, Lee DA, Karpen SJ, Lee TC, Patel AJ, Finegold M, Goss JA. Liver transplantation for severe hepatic graft-versus-host disease: An analysis of aggregate survival data. Liver Transpl 11(5):525-531, 5/2005. PMID: 15838886.
58. Lee DA, Harris CP, Gresik VM, Rao P, Lau CC. Granulocytic sarcoma presenting as pneumonia in a child with t(8;21) acute myelogenous leukemia: diagnosis by fluorescent in situ hybridization. J Pediatr Hematol Oncol 26(7):431-4, 2004. PMID: 15218417.
59. Wang HY*,Lee DA,*, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF. Tumor-specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy. Immunity 20(1):107-118 (*co-first authors), 2004. PMID: 14738769.
60. Lee DA, Molinaro GA. Activated peripheral T lymphocytes undergo apoptosis when cultured with monocytes activated by HLA class II ligation. Cell Immunol 225(2):101-112, 10/2003. PMID: 14698144.
61. Lee DA, Eby WC, Molinaro GA. HIV false positivity after hepatitis B vaccination. Lancet 339(8800):1060, 1992. PMID: 1349089.
62. Liao GP, Harting MT, Hetz RA, Walker PA, Shah SK, Jimenez F, Kosmach SC, Day M,Lee DA, Worth LL, Cox CS. Autologous BMMNCs REduce Therapeutic Intensity for Sever TBI in Children. Pediatric Critical Care Medicine Journal. Submitted.

Book Chapters

1. Tarek N, Lee DA. Natural Killer Cells for Osteosarcoma. In: Adv Exp Med Biol. 804. Ed(s) Kleinerman ES. Springer, 341-53, 2014. ISBN: 24924184.
2. Lee DA, Cooper LJN, Shpall EJ. NK Cell Immunotherapy for AML, in Targeted Therapy of Acute Leukemias. In: Springer, NY, NY. Ed(s) Andreef M. Springer, 2014.
3. Lee DA, Mahoney D. Emergencies in pediatric cancer patients. In: UpToDate, Rose, BD (Ed): Wellesley, MA, 2011.
4. Hurwitz RL, Lee DA. Childhood lead poisoning: Clinical manifestations and diagnosis. In: UpToDate, Rose, BD (Ed): Wellesley, MA, 2002.
5. Lee DA, Hurwitz RL. Childhood lead poisoning: Exposure and prevention. In: UpToDate, Rose, BD (Ed): Wellesley, MA, 2002.
6. Hurwitz RL, Lee DA. Childhood lead poisoning: Treatment. In: UpToDate, Rose, BD (Ed): Wellesley, MA, 2002.

Books (edited and written)

1. Baker DW, Elwin-Jasionowski SC, Lee DA. Talking and Listening. In: N/A. LLU Office of Diversity: Loma Linda, CA, 1994.

Letters to the Editor

1. Molinaro GA, Lee DA, Parashar UD. Rotavirus vaccines. N Engl J Med 354(16):1747-1751, 2006. PMID: 16625014.
2. Lee DA, Mueller BU. Long-term use of hydroxyurea for sickle cell anemia. JAMA 290(6):753-754 (2003 ISI IF 21.455), 8/2003. PMID: 12915425.
3. Lee DA. Home Delivery. The New Physician 12:3, 1993.

Grant & Contract Support

Title: Cell Therapy for AML
Funding Source: MDACC Moonshot
Role: Collaborator
Duration: 12/1/2013 - 11/30/2015
 
Title: Targeting NK Cell Immunotherapy Against AML-LSC
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2013 - 9/30/2016
 
Title: Multimodal Immunotherapy for Neuroblastoma
Funding Source: St. Baldrick's Foundation
Role: Principal Investigator
Duration: 7/1/2013 - 6/30/2016
 
Title: NK cell therapy of 4th ventricle brain tumors
Funding Source: CURE
Role: Co-Principal Investigator
Duration: 7/1/2013 - 6/30/2016
 
Title: Single-Cell Biomarkers of Clinical-Grade T Cells and NK Cells to Optimize Tumor Immunotherapy
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Principal Investigator
Principal Investigator: Navin Varadarajan
Duration: 12/1/2012 - 11/30/2015
 
Title: Cellular Therapy for Cancer (total) Adoptive Immunotherapy with NK Cells Expanded ex vivo for Treatment of AML (project 3)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator on project 3
Principal Investigator: Brenner, Malcolm
Duration: 5/1/2011 - 4/30/2016
 
Title: Innate Immune Effects of Post-Stem Cell Transplant Vidaza
Funding Source: Celgene Corporation
Role: Principal Investigator
Duration: 5/2009 - 4/2016
 
Title: Pediatric Oncology Clinical Research Training Program
Funding Source: NIH/NCI
Role: Trainee
Principal Investigator: David Poplack
Duration: 7/1/2003 - 6/30/2006

Last updated: 8/5/2015